00:41 , Mar 25, 2017 |  BioCentury  |  Strategy

Mountain climbing

U.S. pricing pressure on insulin and hemophilia products have caused Novo Nordisk A/S to guide for negative sales and operating profit growth for the first time ever. While newly launched diabetes and obesity products are...
01:20 , Sep 3, 2014 |  BC Extra  |  Company News

Novo Nordisk discontinues inflammation R&D

Novo Nordisk A/S (CSE:NVO; NYSE:NVO) is discontinuing all inflammatory disease R&D. Novo ended development of its lead compound in the space, NN8226 , which is a recombinant human mAb neutralizing IL-20 in Phase II trials...
08:00 , Feb 10, 2014 |  BC Week In Review  |  Clinical News

Anti-IL-21: Development discontinued

Novo Nordisk disclosed in its 2013 earnings that it discontinued development of NN8828 for RA based on Phase IIa data. NN8828 is in Phase IIa testing to treat Crohn's disease (CD) and Phase I testing...
08:00 , Nov 15, 2010 |  BC Week In Review  |  Clinical News

Anti-IL-21: Phase I started

In September, Novo Nordisk began a double-blind, placebo-controlled, German Phase I trial to evaluate IV and subcutaneous anti-IL-21 in 56 RA patients and healthy volunteers. Novo Nordisk A/S (CSE:NVO; NYSE:NVO), Bagsvaerd, Denmark   Product: Anti-IL-21...
07:00 , Sep 3, 2009 |  BC Innovations  |  Distillery Therapeutics

Indication: Autoimmune disease

Indication Target/marker/pathway Summary Licensing status Publication and contact information Autoimmune disease Psoriasis IL-21 Studies in mice suggest that inhibiting IL-21 could help treat psoriasis. In skin samples from human psoriasis lesions, IL-21 protein and mRNA...